Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.
Spruce Biosciences, Inc. (SPRB) generates news that centers on its late-stage biopharmaceutical efforts to develop and commercialize therapies for neurological disorders with significant unmet medical need. Company announcements focus heavily on tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB), an ultra-rare, serious, and fatal genetic disease for which Spruce states there are currently no FDA-approved treatments.
News coverage for SPRB commonly includes clinical and regulatory milestones. Examples from company releases include integrated long-term clinical data for TA-ERT, demonstrating profound and durable reductions in cerebral spinal fluid heparan sulfate non-reducing end (CSF HS-NRE) and stabilization of cognition and cortical grey matter volume, as well as the U.S. FDA granting Breakthrough Therapy Designation for TA-ERT and confirming CSF HS-NRE as a surrogate biomarker reasonably likely to predict clinical benefit.
Investors also see financing and capital markets updates in Spruce’s news flow. The company has reported a private placement with institutional investors expected to provide approximately $50.0 million in gross proceeds to advance TA-ERT, and a loan and security agreement with Avenue Venture Opportunities Fund II, L.P. providing access to up to $50.0 million in term loans tied to regulatory and commercial milestones. Additional headlines cover reverse stock split actions, conditional approval and resumption of trading on the Nasdaq Capital Market, and related listing matters.
Corporate governance and pipeline diversification are further themes in SPRB news. Spruce has announced board changes, including the appointment of Keli Walbert to its board of directors and compensation committee, as well as director resignations. The company has also issued updates on tildacerfont, being studied in major depressive disorder under a collaboration with HMNC Holding GmbH, and referenced SPR202 for congenital adrenal hyperplasia. For readers tracking SPRB, this news page provides a centralized view of the company’s clinical progress, regulatory interactions, financing events, and governance developments.
Spruce Biosciences presented positive results from its Phase 2 POWER study on tildacerfont, targeting polycystic ovary syndrome (PCOS), at ENDO 2024. Tildacerfont, a CRF1 receptor antagonist, significantly reduced DHEAS levels and increased SHBG levels versus placebo in women with elevated baseline DHEAS. These results suggest potential therapeutic benefits, including a reduction in health risks linked to hyperandrogenism. The study involved 27 women and showed that tildacerfont was well-tolerated with no serious adverse effects.
Spruce Biosciences, a late-stage biopharmaceutical company specializing in therapies for rare endocrine disorders, will participate in the Jefferies Global Healthcare Conference.
CEO Javier Szwarcberg will present on June 5, 2024, at 5:00 p.m. ET.
The presentation will be accessible via a live webcast, with an archived version available for 90 days on the company's investor relations website.
Spruce Biosciences (Nasdaq: SPRB) announced that three abstracts have been accepted for presentation at the 106th Annual Meeting of the Endocrine Society (ENDO 2024), taking place from June 1-4, 2024, in Boston.
The company will present final results from its Phase 2 POWER study of tildacerfont for the treatment of polycystic ovary syndrome (PCOS). Additionally, they will highlight comorbidities associated with congenital adrenal hyperplasia (CAH) and the importance of transitionary care between pediatric and adult endocrinology practices for CAH patients.
Spruce Biosciences (Nasdaq: SPRB), a biopharmaceutical company, reported its Q1 2024 financial results and provided corporate updates. Key highlights include a 45% reduction in ACTH in the CAHmelia-203 study, correlating higher baseline GC doses and drug compliance with better outcomes. The company anticipates topline data from CAHmelia-204 and CAHptain-205 in Q3 2024. Financially, Spruce reported $81.2 million in cash reserves, $2 million in collaboration revenue, and a net loss of $11.6 million, improving from $12.8 million YoY. R&D expenses decreased to $10.3 million, while G&A expenses rose to $4.3 million. Total operating expenses were $14.6 million, down from $15.2 million a year ago. Upcoming milestones include Phase 2 data and an FDA meeting in early 2025.
Spruce Biosciences, Inc. (Nasdaq: SPRB) will participate in two upcoming investor conferences in May, featuring Fireside chats and 1x1 meetings. The events will include the JMP Securities Life Sciences Conference on May 13-14, 2024, and the RBC Capital Markets Global Healthcare Conference on May 14-15, 2024. The CEO, Javier Szwarcberg, M.D., M.P.H., will be presenting at these conferences, with webcasts available on the company's investor relations website.
Spruce Biosciences, Inc. announced additional poster presentations at the Pediatric Endocrine Society 2024 Annual Meeting, highlighting baseline characteristics of their CAHptain program for children with congenital adrenal hyperplasia (CAH) and the CAHmelia program for adults with CAH. The company is focused on developing therapies for rare endocrine disorders and will present abstracts at the conference in Chicago, IL.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Spruce Biosciences (SPRB)?
What is the market cap of Spruce Biosciences (SPRB)?
